NO20075453L - Sammensetning inneholdende antidemensmiddel - Google Patents

Sammensetning inneholdende antidemensmiddel

Info

Publication number
NO20075453L
NO20075453L NO20075453A NO20075453A NO20075453L NO 20075453 L NO20075453 L NO 20075453L NO 20075453 A NO20075453 A NO 20075453A NO 20075453 A NO20075453 A NO 20075453A NO 20075453 L NO20075453 L NO 20075453L
Authority
NO
Norway
Prior art keywords
composition
antidepressant drugs
present
types
composition containing
Prior art date
Application number
NO20075453A
Other languages
English (en)
Inventor
Yosuke Ueki
Susumu Kimura
Masami Nohara
Yukifumi Dota
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NO20075453L publication Critical patent/NO20075453L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

Det er en hensikt ved den foreliggende oppfinnelsen å tilveiebringe, i forbindelse med å implementere en terapeutisk fremgangsmåte hvor det anvendes minst to typer av antidemensmedikamenter sammen, en sammensetning som har god terapeutisk effekt på demens og som dessuten har utmerket brukervennlighet. Det er en annen hensikt ved den foreliggende oppfinnelsen å tilveiebringe en sammensetning som inneholder minst to typer av antidemensmedikamenter hvor frigjøringen av antidemensmedikamentene fra sammensetningen er kontrollert, hvorved man kan oppnå en god samlet effekt av antidemensmedikamentene. Enn videre er det en hensikt ved den foreliggende oppfinnelsen å tilveiebringe en sammensetning hvor administreringsfrekvensen og den mengde som inntas er redusert, hvorved brukervennligheten kan bedres, foruten en fremgangsmåte for fremstilling av en slik sammensetning. Ifølge den foreliggende oppfinnelsen er det tilveiebrakt en sammensetning som inneholder minst to typer av antidemensmedikamenter og hvor en slik sammensetning inneholder minst én vedvarende frigjørende del som inneholder et antidemensmedikament og hvor en slik sammensetning inneholder minst én kolinesterasehemmer og hvor en slik sammensetning inneholder minst én kolinesterasehemmer og minst én N-rnetyl-D-asparatreseptorantagonist.
NO20075453A 2005-04-28 2007-10-29 Sammensetning inneholdende antidemensmiddel NO20075453L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2005132593 2005-04-28
PCT/JP2006/309021 WO2006118265A1 (ja) 2005-04-28 2006-04-28 抗痴呆薬を含有する組成物

Publications (1)

Publication Number Publication Date
NO20075453L true NO20075453L (no) 2008-01-28

Family

ID=37308059

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20075453A NO20075453L (no) 2005-04-28 2007-10-29 Sammensetning inneholdende antidemensmiddel

Country Status (14)

Country Link
US (2) US20090023778A1 (no)
EP (1) EP1878444B1 (no)
JP (1) JP5597343B2 (no)
KR (1) KR101213345B1 (no)
CN (1) CN101166543B (no)
AU (1) AU2006241771B2 (no)
BR (1) BRPI0608780A2 (no)
CA (1) CA2604617C (no)
IL (1) IL186179A0 (no)
NO (1) NO20075453L (no)
NZ (1) NZ562120A (no)
RU (1) RU2445092C2 (no)
WO (1) WO2006118265A1 (no)
ZA (1) ZA200708580B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
NZ555693A (en) 2004-12-27 2010-10-29 Eisai R&D Man Co Ltd Matrix type sustained-release preparation containing donepezil
EP1898886B1 (en) * 2005-07-01 2019-09-04 Rubicon Research Pvt Ltd. Novel sustained release dosage form
GR20070100405A (el) * 2007-06-26 2009-01-20 Genepharm �.�. Βελτιωμενες φαρμακοτεχνικες μορφες που περιεχουν αναστολεις της ακετυλοχοληνεστερασης και μεθοδοι παρασκευης αυτων
TWI491395B (zh) * 2009-09-30 2015-07-11 Ct Lab Inc 一種內含用以治療神經退化性疾病之立即釋出與長效釋出藥物的口服劑量配方
US20100178307A1 (en) * 2010-01-13 2010-07-15 Jianye Wen Transdermal anti-dementia active agent formulations and methods for using the same
EP2366378A1 (en) 2010-03-01 2011-09-21 Dexcel Pharma Technologies Ltd. Sustained-release donepezil formulations
WO2011127235A1 (en) 2010-04-07 2011-10-13 Eisai Inc. Combination therapy for the treatment of dementia
CN102309460B (zh) * 2010-07-09 2013-04-24 重庆医科大学 溴吡斯的明掩味口腔崩解片及其制备方法
JP5615612B2 (ja) * 2010-07-21 2014-10-29 大原薬品工業株式会社 苦味を有する生理活性物質含有粒子の製造方法
WO2012129759A1 (en) * 2011-03-25 2012-10-04 Center Laboratories, Inc. Oral dosage formulations containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders
TR201104108A2 (tr) * 2011-04-27 2011-08-22 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salımlı memantin tablet.
UA107653U (uk) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" Композиція лікарських засобів для лікування та профілактики поведінкових, психічних та когнітивних розладів
US11160785B2 (en) * 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
WO2015080758A1 (en) * 2013-11-27 2015-06-04 Al-Qahtani Ahmed H Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca
CA2938671A1 (en) * 2014-02-04 2015-08-13 Forest Laboratories Holdings Limited Donepezil compositions and method of treating alzheimer's disease
JP6465376B2 (ja) * 2014-06-16 2019-02-06 株式会社インタラクティブソリューションズ 表示情報管理システム
CN105326837A (zh) * 2015-10-09 2016-02-17 北京万全德众医药生物技术有限公司 一种盐酸美金刚缓释-多奈哌齐速释复方胶囊
KR101938872B1 (ko) * 2016-09-30 2019-01-16 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
WO2018062941A1 (ko) * 2016-09-30 2018-04-05 주식회사 바이오파마티스 도네페질 또는 그의 약학적으로 허용 가능한 염 및 메만틴 또는 그의 약학적으로 허용 가능한 염을 함유하는 치매 및 인지기능 장애 예방 또는 치료용 약학 조성물 및 이의 제조방법
JP6853828B2 (ja) * 2016-10-28 2021-03-31 第一三共株式会社 メマンチンまたはその薬学上許容される塩を含有する医薬組成物
JP7023186B2 (ja) * 2017-05-29 2022-02-21 第一三共株式会社 認知症治療薬を含有する口腔内崩壊性錠剤
KR20190143386A (ko) * 2018-06-20 2019-12-30 센터 래버러토리스 아이엔씨 신경퇴행성 장애를 치료하기 위한 pH 비의존성 경구 투여 제형
KR20210072569A (ko) 2019-12-09 2021-06-17 주식회사 종근당 도네페질 및 메만틴을 포함하는 복합 제제

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2327996A (en) * 1941-11-24 1943-08-31 Thompson W Burnam Process of dehydrating mineral oil emulsions
US4772475A (en) * 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
CA1308357C (en) * 1987-01-28 1992-10-06 Tohru Chiba Method for the preparation of a coated solid medicament
JP2893191B2 (ja) * 1988-11-08 1999-05-17 武田薬品工業株式会社 放出制御性マトリックス剤
US5202128A (en) * 1989-01-06 1993-04-13 F. H. Faulding & Co. Limited Sustained release pharmaceutical composition
NZ233403A (en) * 1989-04-28 1992-09-25 Mcneil Ppc Inc Simulated capsule-like medicament
JPH03193733A (ja) * 1989-12-25 1991-08-23 Nikken Chem Co Ltd テオフィリンの徐放性製剤
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
HU9203780D0 (en) * 1991-12-12 1993-03-29 Sandoz Ag Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
DE4225730C2 (de) * 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
US5474995A (en) * 1993-06-24 1995-12-12 Merck Frosst Canada, Inc. Phenyl heterocycles as cox-2 inhibitors
US5698224A (en) * 1994-06-27 1997-12-16 Alza Corporation Tacrine therapy
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US5871776A (en) * 1995-01-31 1999-02-16 Mehta; Atul M. Controlled-release nifedipine
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
JPH09188617A (ja) * 1996-01-08 1997-07-22 Pola Chem Ind Inc 徐放性医薬組成物
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
ATE302599T1 (de) * 1996-05-24 2005-09-15 Angiotech Pharm Inc Zubereitungen und verfahren zur behandlung oder prävention von krankheiten der körperpassagewege
JPH1017497A (ja) * 1996-07-02 1998-01-20 Takeda Chem Ind Ltd 徐放性製剤およびその製造方法
US6310085B1 (en) * 1997-10-03 2001-10-30 Clarencew Pty Ltd. Method for the treatment of neurological or neuropsychiatric disorders
DE19707655A1 (de) * 1997-02-26 1998-08-27 Hoechst Ag Kombinationspräparat zur Anwendung bei Demenz
EP0988289A2 (en) * 1997-06-05 2000-03-29 Takeda Pharmaceutical Company Limited Heterocyclic compounds, their production and use
US20040028735A1 (en) * 1997-11-14 2004-02-12 Unchalee Kositprapa Pharmaceutical formulation
US20030092737A1 (en) * 1997-11-14 2003-05-15 Pierre Maffrand Jean Combination of active ingredients for the treatment of senile dementia of the Alzheimer type
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6262081B1 (en) * 1998-07-10 2001-07-17 Dupont Pharmaceuticals Company Composition for and method of treating neurological disorders
KR100764520B1 (ko) * 1998-08-28 2007-10-09 에자이 알앤드디 매니지먼트 가부시키가이샤 고미 등을 경감한 의약조성물
US20010055613A1 (en) * 1998-10-21 2001-12-27 Beth A. Burnside Oral pulsed dose drug delivery system
DK1140105T3 (da) * 1998-12-24 2004-02-23 Janssen Pharmaceutica Nv Galantaminpræparat med styret frigivelse
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6340965B1 (en) * 1999-03-18 2002-01-22 Xerox Corporation Modifiable display having fixed image patterns
IL145661A0 (en) * 1999-03-31 2002-06-30 Janssen Pharmaceutica Nv Pregelatinized starch in a controlled release formulation
US20020107173A1 (en) * 1999-11-04 2002-08-08 Lawrence Friedhoff Method of treating amyloid beta precursor disorders
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US20030144255A1 (en) * 2000-03-06 2003-07-31 Bain Allen I Compositions for prevention and treatment of dementia
IN192159B (no) * 2000-05-15 2004-02-28 Ranbaxy Lab Ltd
DE10029201A1 (de) * 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
SE0004671D0 (sv) * 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
CA2350195C (en) * 2000-12-20 2003-06-10 Duchesnay Inc. Rapid onset formulation of pyridoxine hydrochloride and doxylamine succinate
US6287599B1 (en) * 2000-12-20 2001-09-11 Shire Laboratories, Inc. Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
US6667070B1 (en) * 2001-02-02 2003-12-23 Advanced Micro Devices, Inc. Method of in situ monitoring of thickness and composition of deposited films using raman spectroscopy
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
JP2004534812A (ja) * 2001-06-22 2004-11-18 ファイザー・プロダクツ・インク 薬物および中性ポリマーの分散物の医薬組成物
DE60237826D1 (de) * 2001-07-27 2010-11-11 Astellas Pharma Inc Zusammensetzung enthaltend feine Körner mit verzögerter Freisetzung für in der Mundhöhle schnell zerfallende Tabletten
JP4848101B2 (ja) * 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
EP1429739A1 (en) * 2001-09-21 2004-06-23 Egalet A/S Polymer release system
MXPA04002980A (es) * 2001-09-28 2005-06-20 Johnson & Johnson Formas de dosificacion que tienen un nucleo interior y coraza exterior con diferentes formas.
US20030118649A1 (en) * 2001-10-04 2003-06-26 Jinming Gao Drug delivery devices and methods
SI1443917T1 (sl) * 2001-11-07 2006-06-30 Synthon Bv Tablete tamsulozina
WO2003053402A1 (en) * 2001-12-20 2003-07-03 Pharmacia Corporation Zero-order sustained released dosage forms and method of making the same
KR100540035B1 (ko) * 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
JP5105684B2 (ja) * 2002-03-15 2012-12-26 大塚製薬株式会社 持続性医薬製剤
AU2003225102A1 (en) * 2002-04-23 2003-11-10 Bristol-Myers Squibb Company Modified-release vasopeptidase inhibitor formulation, combinations and method
WO2003096874A2 (en) * 2002-05-15 2003-11-27 Sun Pharmaceutical Industries Limited Coated sustained release tablets of a hygroscopic compound for once-a-day therapy
DE60324788D1 (de) * 2002-05-31 2009-01-02 Lundbeck & Co As H Kombination aus einem nmda-antagonist und acetylcholinesterase-hemmern zur behandlung der alzheimer-krankheit
WO2004017938A2 (en) * 2002-08-23 2004-03-04 Ranbaxy Laboratories Limited Nitrofurantoin controlled release dosage form
US20040052844A1 (en) * 2002-09-16 2004-03-18 Fang-Hsiung Hsiao Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins
CN100339070C (zh) * 2002-10-24 2007-09-26 莫茨药物股份两合公司 包含1－氨基环己烷衍生物类和乙酰胆碱酯酶抑制剂类的药物组合物
US7988993B2 (en) * 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
WO2004058309A1 (en) * 2002-12-23 2004-07-15 Human Genome Sciences, Inc. Neutrokine-alpha conjugate, neutrokine-alpha complex, and uses thereof
AU2004207523A1 (en) * 2003-01-24 2004-08-12 Control Delivery Systems, Inc. Controlled release of highly soluble agents
US20040185097A1 (en) * 2003-01-31 2004-09-23 Glenmark Pharmaceuticals Ltd. Controlled release modifying complex and pharmaceutical compositions thereof
CA2519208A1 (en) * 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
TW200508197A (en) 2003-03-31 2005-03-01 Ucb Sa Indolone-acetamide derivatives, processes for preparing them and their uses
US20060210633A1 (en) * 2003-04-03 2006-09-21 Sun Pharmaceutical Industries Limited Programmed drug delivery system
MXPA05010636A (es) * 2003-04-04 2005-12-12 Pharmacia Corp Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada.
US20040208928A1 (en) * 2003-04-15 2004-10-21 Animal Technology Institute Taiwan Method for preparing an orally administrable formulation for controlled release
KR20060033727A (ko) * 2003-06-16 2006-04-19 알러간, 인코포레이티드 메만틴 경구 투여 제형
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
US20090208579A1 (en) * 2004-12-27 2009-08-20 Eisai R & D Management Co., Ltd. Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same
NZ555693A (en) * 2004-12-27 2010-10-29 Eisai R&D Man Co Ltd Matrix type sustained-release preparation containing donepezil
KR101022857B1 (ko) * 2008-01-16 2011-03-17 인하대학교 산학협력단 수소저장용 전이금속 도금된 다공성 탄소나노섬유 복합체의제조방법

Also Published As

Publication number Publication date
EP1878444A1 (en) 2008-01-16
EP1878444A4 (en) 2010-08-04
CN101166543B (zh) 2014-07-16
JPWO2006118265A1 (ja) 2008-12-18
KR101213345B1 (ko) 2012-12-17
BRPI0608780A2 (pt) 2010-11-09
AU2006241771B2 (en) 2010-09-09
AU2006241771A1 (en) 2006-11-09
ZA200708580B (en) 2008-10-29
US20140099366A1 (en) 2014-04-10
CN101166543A (zh) 2008-04-23
WO2006118265A1 (ja) 2006-11-09
RU2445092C2 (ru) 2012-03-20
EP1878444B1 (en) 2015-09-09
CA2604617A1 (en) 2006-11-09
IL186179A0 (en) 2008-01-20
JP5597343B2 (ja) 2014-10-01
KR20080005234A (ko) 2008-01-10
NZ562120A (en) 2010-07-30
US20090023778A1 (en) 2009-01-22
RU2007139712A (ru) 2009-05-10
CA2604617C (en) 2014-06-17

Similar Documents

Publication Publication Date Title
NO20075453L (no) Sammensetning inneholdende antidemensmiddel
WO2007135527A3 (en) Benzimidazolyl compounds
TNSN08405A1 (en) Cyclohexylpyrazole - lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
WO2008060907A3 (en) Pyrrolo-pyridine kinase inhibitors
UA102582C2 (en) Oral dosage forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione
NZ564696A (en) Glucocorticoid, indazole, mimetics, methods of making them, pharmaceutical compositions, and uses thereof
MA51204B1 (fr) Formes pharmaceutiques comprenant un inhibiteur de la kallicréine plasmatique
MX336881B (es) Compuestos heterociclicos triciclicos.
EA200970088A1 (ru) Модуляторы метаболизма и лечение связанных с ним нарушений
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
EA201400056A1 (ru) Вещества, связывающие ядерные рецепторы
RS20090036A (en) Pyrazole derivatives as cytochrom p450 inhibitors
MA30686B1 (fr) Inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase.
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
WO2008027542A3 (en) 5-substituted isoindoline compounds
NO20091938L (no) 7,8-dihydro-1,6-naftyridin-5(6H)-oner og relaterte bicykliske forbindelser som inhibitorer av dipeptidyl-peptidaser IV og metoder
ATE482210T1 (de) Oxadiazolderivate als s1p1-rezeptor-agonisten
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
EA200970835A1 (ru) Индазолы, применяемые для лечения расстройств, опосредуемых эстрогеновым рецептором бета
WO2006025070A3 (en) Nebivolol and its pharmaceutically acceptable salts, process for preparation and pharmaceutical compositions of nebivolol
UA92670C2 (ru) Пиразолиновые соединения и их фармацевтическое применение, композиция на их основе
EA200870302A1 (ru) 1,3-диоксанкарбоновые кислоты
BR112012027640A2 (pt) composto, composição farmacêutica uso de um composto, e, métodos de preparar uma composição farmacêutica, de inibir a função da 11beta-hidroxiesteroide desidrogenase do tipo 1 e de tratamento ou prevenção de um distúrbio
WO2008035359A3 (en) Oximinophenoxyalkanoic acid and phenylalkanoic acid derivatives
MY150474A (en) 6h-dibenzo [b,e] oxepine derived nonsteroidal mineralocorticoid receptor antogonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application